Trial Profile
Prospective Phase II Randomized Trial of Evaluating the Effect of Adding LHRH Analogue to the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer on Pathologic Complete Response (pCR) Rates
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms NeoGONT
- 27 Feb 2018 New trial record